Jazz Pharmaceuticals to Present Key Oncology Data at ASCO 2026
Event summary
- Jazz Pharmaceuticals will present 10 data sets at ASCO 2026, including 3 rapid oral presentations and 7 posters.
- Key focus on Ziihera (zanidatamab-hrii) for HER2+ gastroesophageal adenocarcinoma and Zepzelca (lurbinectedin) for small cell lung cancer.
- Data includes Phase 3 trial results for Ziihera combinations and real-world evidence for Zepzelca.
- Presentations cover PD-L1 subgroup analyses, molecular subtypes, and safety profiles.
- ASCO 2026 takes place May 29-June 2, 2026 in Chicago.
The big picture
Jazz Pharmaceuticals is reinforcing its position in oncology with these ASCO presentations, particularly in difficult-to-treat cancers like HER2+ gastroesophageal adenocarcinoma and small cell lung cancer. The focus on real-world evidence and molecular subgroup analyses reflects the industry's shift toward precision medicine approaches. These data presentations could significantly impact Jazz's regulatory and commercial strategies in 2026 and beyond.
What we're watching
- Regulatory Pathways
- Whether the HERIZON-GEA-01 trial data will support zanidatamab's supplemental biologics license application for first-line HER2+ GEA.
- Market Differentiation
- How the Zepzelca combination therapy data will position Jazz in the competitive small cell lung cancer maintenance treatment space.
- Pipeline Momentum
- The pace at which Jazz can translate these oncology advancements into commercial success and expanded indications.
Related topics